WAVE Life Sciences Ltd (STU:1U5)
€ 5.05 +0.13 (+2.64%) Market Cap: 983.30 Mil Enterprise Value: 518.88 Mil PE Ratio: 0 PB Ratio: 2.19 GF Score: 66/100

WAVE Life Sciences Ltd at JPMorgan Healthcare Conference Transcript

Jan 13, 2026 / 10:15PM GMT
Release Date Price: €12.2 (+2.52%)
Tessa Romero
JPMorgan Chase & Co - Analyst

Welcome, everyone, to the 44th Annual JPMorgan Healthcare Conference. My name is Tess Romero, and I'm one of the senior biotech analysts here at JPMorgan. Our next presenting company is Wave Life Sciences and presenting on behalf of the company, we have President and CEO, Paul Bolno. Over to you.

Paul Bolno
WAVE Life Sciences Ltd - President, Chief Executive Officer, Director

Thank you, Tessa, and thank you, everybody, for joining us today. Before we start, we'll obviously be making some forward-looking statements during this call, so I'd please ask you to refer to our SEC filings for updates. Taking a pause and thinking about entering 2026, we are energized now more than ever to unlock the broad potential of RNA medicines and open up the opportunity to transform human health. And what this really reflects back on as a journey on building a leading RNA medicines company and at the foundation. And this is going to be important as we speak to the evolution of the clinical portfolio is the financial bedrock of wave

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot